Abstract 785P
Background
GTN involves malignant entities, such as choriocarcinoma (GCC), epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT), all of which can metastasize and be fatal if not treated in a timely and effective manner. We aimed to develop machine-learning (ML)-based prognostic models for patients with GTN to improve treatment decisions and personalized medicine.
Methods
The SEER database provided the data used for this study’s analysis (2000–2019). Patients were excluded if they did not meet certain criteria, such as a histology-confirmed diagnosis, previous history of cancer or other concurrent malignancies, non-placental origins, or unknown data. Cox regression and ML algorithms were used to construct prognostic models for predicting the 5-year survival. Patient records were randomly divided into a training set (70%) and a validation set (30%). A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of ML models.
Results
This study included 725 patients, of whom 139 had ETT, 107 had PSTT, and 479 had GCC. The median age was 37 years, and the most common stage was distant metastasis (n=330). The average tumor size was 6.13 cm, and 75.9% of patients underwent chemotherapy, 57.9% underwent surgery, and 4.3% underwent radiotherapy. Multivariate Cox regression revealed that older age, marital status, metastasis, and radiotherapy were poor prognostic factors, whereas surgery was a good prognostic factor. ML models revealed that the most important factors that influenced the model prediction performance were tumor size, years of diagnosis, and race. The online calculator, which is based on ML models, allows for real-time personalized survival predictions, and can be accessed through the following link: https://sakhrshwayyat.shinyapps.io/Gestational_Trophoblastic_Neoplasia/.
Conclusions
Our study revealed the critical components of clinical decision-making. The designed models and online prediction resources can significantly facilitate personalized treatment planning and enhance the clinical outcomes of patients with GTN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
861P - Neo-TIME trial: Neoadjuvant tislelizumab combined with albumin-paclitaxel, cisplatin, and fluorouracil(APF) in patients with locally advanced oral squamous cell carcinoma (LA-OSCC)
Presenter: Wenquan Zhao
Session: Poster session 02
862P - Neoadjuvant chemo-immunotherapy using carboplatin, nab-paclitaxel, oral metronomic therapy and low dose nivolumab for “borderline resectable” oral cavity carcinoma: A prospective phase II single-arm trial (NeoLOCUS)
Presenter: Praveen Kumar Marimuthu
Session: Poster session 02
863P - Safety and efficacy of four courses of pembrolizumab combined with carboplatin and albumin-binding paclitaxel versus two courses of neoadjuvant therapy in patients with resectable head and neck squamous cell carcinoma: An optimal efficacy study (prospective, two-arm, phase II)
Presenter: Jinsong Li
Session: Poster session 02
Resources:
Abstract
866P - Neoadjuvant and adjuvant AK104 in patients with recurrent, resectable squamous cell carcinoma of the head and neck: A phase II study
Presenter: Lei Liu
Session: Poster session 02
868P - Phase II trial of ozuriftamab vedotin (BA3021), a conditionally active biologic (CAB)-ROR2-ADC, in patients with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
Presenter: Winston Wong
Session: Poster session 02
869P - Results of the multicenter phase II FRAIL-IMMUNE trial evaluating the efficacy and safety of durvalumab (D) combined with weekly paclitaxel carboplatin in 1st-line in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) not eligible to cisplatin
Presenter: Jérome Fayette
Session: Poster session 02